pulmonaryembolism ....tanmay new
TRANSCRIPT
Dr. TANMAY JAINResident , Chest MedicineGMC, NAGPUR
1
GoalsUnderstand the historical context of pulmonary
emboli
Comprehend the pathophysiology and know some common risk factors
Be aware of the clinical features of PE and have a basic understanding of various diagnostic test
Gain a therapeutic approach to the treatment of PE and discuss a simplified method in the work-up of PE
Attempt to dispel a few “myths”about pulmonary emboli
2
PerspectiveA Common disorder and potentially lethal
630,000 cases occurring annually with 2,00000 related deaths
Highest incidence in hospitalized patients
Autopsy reports suggest it is commonly “missed” diagnosed
3
Perspective Presentation is often “atypical”
Signs and symptoms are frequently vague and nonspecific and rarely “classic”
Untreated mortality rate of 20% - 30%, plummets to 5% with timely intervention
4
Historical ContextPre-1930’s
Heparin
Eugine Robin article (1977)
5
Historical Context
PIOPED (Prospective Investigation of Pulmonary Embolism Diagnosis) 1990
Published their data on the sensitivities and specificities of V/Q scans for PE.
6
Why care????? PE is the most common preventable cause of death
in hospitalized patients ~600,000 deaths/year 80% of pulmonary emboli occur without prior
warning signs or symptoms 2/3 of deaths due to pulmonary emboli occur
within 30 minutes of embolization Death due to massive PE is often immediate Diagnosis can be difficult Early treatment is highly effective
7
PathophysiologyRudolph Virchow, 1858
Triad: Hypercoagulability Stasis to flow Vessel injury
8
9
10
Risk FactorsHypercoagulabilityMalignancy
Nonmalignant thrombophiliaPregnancyPostpartum status (<4wk)Estrogen/ OCP’s Genetic mutations (Factor V Leiden, Protein
C & S deficiency, Prothrombin mutations, anti-thrombin III deficiency)
Anti cardiolipin abNephrotic syndromeIBDPNHDICEssential thrombocytosis
11
Venous Stasis Prior venous thrombosis Bedrest > 24 hr
Recent cast or external fixatorLong-distance travel or prolong automobile travel
CHF,
Vessel wall InjuryRecent surgery requiring endotracheal intubationRecent trauma (especially the lower extremities,head and pelvis)
12
Natural History of VTE-(80%–95%) of PE occur as a result of
thrombus originating in the lower extremity.
40-50% of pts with DVT develop PE, often “silent”
PE presents 3-7 days after DVTFatal within 1 hour after onset of respiratory
symptoms in 10%Shock/persistent hypotension in 5-10% (up to
50% of patients with RV dysfunction)Most fatalities occur in untreated pts
13
Clinical Presentation The Classic Triad: (Hemoptysis, Dyspnea,
Pleuritic Pain)
Not very common! Occurs in less than 20% of patients with
documented PE Syncope=rare presentation, but indicates
severely reduced hemodynamic reserve
In pts with pre-existing CHF or COPD, worsening dyspnea may indicate PE
14
Three Clinical Presentations
Pulmonary Infarction -have pleuritic chest pain
Submassive Embolism
Massive Embolism -a clot which obstructs two lobar arteries, so-called “Saddle Embolus”. Acute cor pulmonale
15
Mythology of PEMyth
“Patients with pulmonary embolism are short of breath and have chest pain!”
16
Clinical Features Symptoms in Patients with Angio Proven
PTE
Symptom Percent
Dyspnea 84Chest Pain, pleuritic 74Anxiety 59Cough 53Hemoptysis 30Sweating 27Chest Pain, nonpleuritic 14Syncope 13
17
Clinical Features Signs with Angiographically Proven PE
Sign Percent
Tachypnea > 20/min 92Rales 58Accentuated S2 53Tachycardia >100/min 44Fever > 37.8 43Diaphoresis 36S3 or S4 gallop 34
Thrombophebitis 32Lower extremity edema 24
18
Who do we work up?-
Transition from tech oriented approach to bayesian analysis.
Pretest Probability
Helps in the selection and interpretation of futher diagnostic tests to create a post test probablity
19
20
Ingredients for a Proper Dx
Clinical Suspicion,Signs and SxsRisk FactorsLab Tests
IMAGING21
Diagnostic Test Imaging Studies
CXR V/Q ScansHRCT MRICTPAPulmonary Angiography EchocardiograpyDuplex USG
Laboratory Analysis CBC, ESR, Hgb/Hct, D-Dimer ABG’s
Ancillary Testing EKG Pulse Oximetry
22
Diagnostic Testing- CXR’s
Chest X-Ray Myth:
“You have to do a chest x-ray so you can find Hampton’s hump or a Westermark sign.”
Reality:
Most chest x-rays in patients with PE are nonspecific and insensitive
23
Diagnostic Testing - CXR’s
Chest radiograph findings in patient with pulmonary embolism
CardiomegalyNormal studyAtelectasis Elevated HemidiaphragmPulmonary Artery EnlargementPleural EffusionParenchymal Pulmonary Infiltrate
24
Chest X-ray Eponyms of PEWestermark's sign
A dilation of the pulmonary vessels proximal to the embolism along with collapse of distal vessels, sometimes with a sharp cutoff.
Hampton’s Hump
A triangular or rounded pleural-based infiltrate with the apex toward the hilum, usually located adjacent to the hilum.
25
26
Westermark’s Sign
Hampton’s Hump
Diagnostic Testing – EKG’s
EKG
Most Common Findings:
Tachycardia or nonspecific ST/T-wave changes
Acute cor pulmonale or right strain patterns
Tall peaked T-waves in lead II (P pulmonale) Right axis deviation RBBB S1-Q3-T3 (specific but occurs in only 20% of PE
patients)(Last three in V1-V3 suggests RV dysfunction)
27
S1Q3T3 & T wave changes
28
Duplex USGMain criteria used is non compressibility of a
venous segment.
29
Diagnostic Testing - Pulse Oximetry
The Pulse Oximetry Myth:
“ You must do a pulse oximetry reading, since patients with pulmonary embolism are hypoxemic!”
Reality:
Most patients with a PE have a normal pulse oximetry, and most patients with an abnormal pulse oximetry will not have a PE.
30
Diagnostic Testing - ABG’s
The ABG/ A-a Gradient myth:
“You must do an arterial blood gas and calculate the alveolar-arterial gradient. Normal A-a gradient virtually rules out PE”.
Reality:
The A-a gradient is a better measure of gas exchange than the pO2, but it is nonspecific and insensitive in ruling out PE.
31
Diagnostic TestingEchocardiography
Consider in every patient with a documented pulmonary embolism EKG maybe helpful in demonstrating right heart
strain
Early fibrinolysis can reduce mortality 50%!
32
D-dimer TestFibrin split product
Circulating half-life of 4-6 hours
Quantitative test have 80-85% sensitivity, and 93-100% negative predictive value
False Positives:
Pregnant Patients Post-partum < 1 weekMalignancy Surgery within 1 weekAdvanced age > 80 years SepsisHemmorrhage CVAAMI Collagen Vascular
DiseasesHepatic Impairment
33
Diagnostic TestingD-dimer
Qualitative Bed side RBC agglutination test
“SimpliRED D-dimer”
Quantitative Enzyme linked immunosorbent asssay “Dimertest” Positive assay is > 500ng/ml VIDAS D-dimer, 2nd generation ELISA test
34
Ventilation/Perfusion Scan- “V/Q Scan”
A common modality to image the lung and its use still stems from the PIOPED study.
Relatively noninvasive and sadly most often nondiagnostic
In many centers remains the initial test of choice
Preferred test in pregnant patients, renal dysfunction
50 mrem vs 800mrem (with spiral CT)
35
36
Ventilation-perfusion scintigraphy
37
Right upper lobe: „match”, Both lower lobes: „mismatch
38
Interpretation Normal Low probability/”nondiagnostic” (most common) High Probability
Simplified approached to the interpretation of results:
High probability Treat for PENormal Scan If low pre-test, your doneEverything else Purse another study (CT, Angio)
39
Spiral (Helical) Chest CTAdvantages
Noninvasive and RapidAlternative Diagnosis
Disadvantages
Risk to patients with borderline renal functionHard to detect subsegmental pulmonary
emboli
40
At the present time, CT can be consideredconfirmatory in excluding embolism in patients with a low or intermediate likelihood of disease andconfirming embolism in patients with intermediate or high probability of disease. When discordanceexists between the clinical assessment and CT findings, additional studies should be considered.
41
Pulmonary Angiography
“Gold Standard”Performed in an Interventional Cath Lab &
invasive. It requires expertise in study, performance &
interpretation.
Positive result is a “cutoff” of flow or intraluminal filling defect
42
CT-PAFirst line investigation at present.Widespread use has resulted in the over
diagnosis of PE, i.e clinically insignificant disease
43
Current diagnostic strategies capable of excluding diagnosis of PE
44
Current diagnostic strategies capable of confirming diagnosis of PE
45
Treatment:
Goals: Prevent death from a current embolic
event
Reduce the likelihood of recurrent embolic events
Minimize the long-term morbidity of the event
46
Dr. Batizy explaining the CT results
When a diagnosis of venous thromboembolism is suspected, empiric treatment should be considered until the diagnosis is either objectively excluded or confirmed.
47
TreatmentAnticoagulants
Heparin Provides immediate thrombin inhibition, which
prevents thrombus extension & embolic recurrence
Does not dissolve existing clot
Will not work in patients with antithrombin III def. In this case use hirudins
Few absolute contraindications
48
TreatmentAnticoagulants
Heparin Available as Unfractionated or LMW Heparin
FDA approved dosing:
Unfractionated: 80 units/kg bolus, 18 units/kg/hr
LMWH: 1 mg/kg every 12hr or 1.5mg/kg per Day
LMWH (Lovenox) prefered in pregnant patients
49
Fixed dose of s/c UFH without aPTT monitoring, as an initial dose of 333 U/kg f/b 250 U/kg every 12 hours, has been demonstrated to be as safe and effective as LMWH in patients presenting with DVT and PE.
LMWH v/s UFH Enoxaparin, Tinzaparin , Nadroparin ,
Dalteparin50
FONDAPARINUXSelectively binds factor Xa and inhibits
thrombin generation.T1/2 17 hrs- renal excr.Approved for prophylaxis before major sx and
for t/t of DVT & PE in conjuction with warfarin.
Rivaroxaban is oral factor Xa inhibitor
51
Direct thrombin inhibitorsLepirudin, Argatroban- synth polysacchrides.T1/2 40-60 mins, i/v infusion, monitering with
aPTT.Approved for t/t of VTE due to heparin IT.
52
Thrombolysis therapy Indications:
Documented PE with: Persistent hypotension Syncope with persistent hemodynamic compromise Significant hypoxemia +/- patient with acute right heart strain
FDA Approved –Alteplase, STK, Urokinase, regimen is 100mg as a continuous IV infusion. PEITHO( PE Thrombolysis trial) – for saftey & efficacy
of Tenectiplase
53
TreatmentEmbolectomy
Prefibrinolytic therapy this was only therapy for massive PE
Carries a 40% operative mortality
Last resort for pts with persistant hypotension,shock who failed thrmbolysis or C/I.
54
Interventional thrombus fragmentationWide variety of devices that use pressured
saline and rotating impellers to break central thrombus.
55
Long term managmentRecurrence commonAnticoagulants
Warfarin (Coumadin) Vit k antagonist
Requires 3-5 days to acieve full therapeutic effecacy
Important a patient is anticoagulated with heparin before initiating warfarin therapy
Target INR is 2.0 – 3.0
56
Side effects- bleeding teratogenic cholesterol microembolismDose – 5mg or 10 mg at the start with
adjustment acc to INR
57
Novel agents for long term m/m1.Dabigatran-oral direct thrombin inhibitor2.Apixaban3.Aspirin – reduces major vascular events
58
VENA CAVA INTERRUPTION AND VENA CAVA FILTER IVC filter placement is to prevent PE in
patients who have a contraindication to anticoagulation
59
CTEPH Residual thromboembolic burden is
sufficiently extensive to cause CTEPH 0.5% to 3.8% in initial episode of PE to
13.4% following recurrent episodes of VTE Pulmonary thromboendarterectomy, which
involves the dissection of endothelialized thrombi under cardiopulmonary bypass and deep hypothermia.
60
PROPHYLAXISUFHLMWH (enoxaparin, dalteparin)Factor Xa inhibitors (fondaparinux,
rivaroxaban) WarfarinWhen administered correctly in appropriate
patients, its safe and effective with an absolute reduction in the incidence of VTE in the range of 40% to 60%.
Major bleeding complications occur in less than 1% of patients
61
ConclusionSummary Points
Pulmonary Emboli remain a potentially deadly and common event which may present in various ways
Don't’ be fooled if your patient lacks the “classic” signs and symptoms!
Consider PE in any patient with an unexplainable cause of dyspnea, pleuritic chest pain, or findings of tachycardia, tachpnea, or hypoxemia
2nd Generation Qualitative D-Dimers have NPV of 93-99%
Heparin remains the mainstay of therapy with the initiation of Warfarin to follow
Simplified Algorithm: ( Pretest probability, D-Dimer, +/- CT angio)
62
Thank you
63